First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced CancersBranimir I. Šikić, Sukhmani K. Padda, Nehal J. Lakhani et al.|Journal of Clinical Oncology|2019Cited by 590
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced CancerToshio Shimizu, Amita Patnaik, Aracely Cavazos et al.|Clinical Cancer Research|2012Cited by 432
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 StudyAditya Bardia, Funda Meric‐Bernstam, Ian E. Krop et al.|Journal of Clinical Oncology|2024Cited by 158
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumorsAlbiruni RA Razak, Kyriakos P. Papadopoulos, James M. Cleary et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 117
First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.Kyriakos P. Papadopoulos, Glenn S. Kroog, Nehal J. Lakhani et al.|Journal of Clinical Oncology|2019Cited by 38